Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis.
Antidepressive Agents
/ administration & dosage
Antipsychotic Agents
/ adverse effects
Clozapine
/ adverse effects
Histamine Antagonists
/ administration & dosage
Humans
Medicine, Chinese Traditional
Muscarinic Antagonists
/ administration & dosage
Randomized Controlled Trials as Topic
Salivation
/ drug effects
Schizophrenia
/ drug therapy
Sialorrhea
/ chemically induced
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
14
2
2019
medline:
3
7
2020
entrez:
14
2
2019
Statut:
ppublish
Résumé
Clozapine is the most effective medication for treatment-refractory schizophrenia. However, it has a high burden of adverse events, including common adverse events such as sialorrhea. Sialorrhea can lead to severe physical complications such as aspiration pneumonia, as well as psychological complications including embarrassment and low self-esteem. Compromised adherence and treatment discontinuation can occur due to intolerability. There have been no meta-analyses examining strategies to mitigate clozapine-induced sialorrhea. We systematically searched Chinese and Western research databases for randomised controlled trials examining agents for clozapine-induced sialorrhea. No limit to language or date were applied to the search. Where sufficient data for individual agents was available, pairwise meta-analyses were conducted. Results were provided as risk ratios and number needed to treat. Sensitivity analysis was conducted by study quality. Adverse events were provided as number needed to harm. 19 studies provided data for use in the meta-analysis. Improvement in clozapine-induced sialorrhea was seen in meta-analyses of propantheline (studies = 6, risk ratio [RR] 2.38, 95% confidence interval [CI] 1.52-3.73; number needed to treat [NNT] 3, 95% CI 1.9-2.7), diphenhydramine (studies = 5, RR 3.09, 95% CI 2.36-4.03; NNT 2, 95% CI 1.5-2.0), chlorpheniramine (studies = 2, RR 2.37, 95% CI 1.59-3.55; NNT 3, 95% CI 1.6-3.5), and benzamide derivatives (odds ratio [OR] 6.93, 95% CI 3.03-15.86). When meta-analyses were limited to high-quality studies, all these results remained significant. Single studies of benzhexol, cyproheptadine, doxepin and Kongyan Tang showed promise. Propantheline increased rates of constipation with a number needed to harm (NNH) of 9 (95% CI 4.2-204.1). Clozapine-induced sialorrhea is a potentially serious adverse event. Included studies in this meta-analysis were limited by poor study quality. Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events. Caution should be exercised when using propantheline given its increased risk of constipation.
Sections du résumé
BACKGROUND
Clozapine is the most effective medication for treatment-refractory schizophrenia. However, it has a high burden of adverse events, including common adverse events such as sialorrhea. Sialorrhea can lead to severe physical complications such as aspiration pneumonia, as well as psychological complications including embarrassment and low self-esteem. Compromised adherence and treatment discontinuation can occur due to intolerability. There have been no meta-analyses examining strategies to mitigate clozapine-induced sialorrhea.
METHODS
We systematically searched Chinese and Western research databases for randomised controlled trials examining agents for clozapine-induced sialorrhea. No limit to language or date were applied to the search. Where sufficient data for individual agents was available, pairwise meta-analyses were conducted. Results were provided as risk ratios and number needed to treat. Sensitivity analysis was conducted by study quality. Adverse events were provided as number needed to harm.
RESULTS
19 studies provided data for use in the meta-analysis. Improvement in clozapine-induced sialorrhea was seen in meta-analyses of propantheline (studies = 6, risk ratio [RR] 2.38, 95% confidence interval [CI] 1.52-3.73; number needed to treat [NNT] 3, 95% CI 1.9-2.7), diphenhydramine (studies = 5, RR 3.09, 95% CI 2.36-4.03; NNT 2, 95% CI 1.5-2.0), chlorpheniramine (studies = 2, RR 2.37, 95% CI 1.59-3.55; NNT 3, 95% CI 1.6-3.5), and benzamide derivatives (odds ratio [OR] 6.93, 95% CI 3.03-15.86). When meta-analyses were limited to high-quality studies, all these results remained significant. Single studies of benzhexol, cyproheptadine, doxepin and Kongyan Tang showed promise. Propantheline increased rates of constipation with a number needed to harm (NNH) of 9 (95% CI 4.2-204.1).
CONCLUSION
Clozapine-induced sialorrhea is a potentially serious adverse event. Included studies in this meta-analysis were limited by poor study quality. Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events. Caution should be exercised when using propantheline given its increased risk of constipation.
Identifiants
pubmed: 30758782
doi: 10.1007/s40263-019-00612-8
pii: 10.1007/s40263-019-00612-8
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Histamine Antagonists
0
Muscarinic Antagonists
0
Clozapine
J60AR2IKIC
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-238Références
Ther Adv Psychopharmacol. 2016 Jun;6(3):178-84
pubmed: 27354906
Aust N Z J Psychiatry. 2018 Aug;52(8):751-767
pubmed: 29732913
Int Clin Psychopharmacol. 2006 Mar;21(2):99-103
pubmed: 16421461
J Clin Psychopharmacol. 2016 Jun;36(3):200-5
pubmed: 27028980
Acta Psychiatr Scand. 2017 Apr;135(4):296-309
pubmed: 28155220
Ann Pharmacother. 2011 May;45(5):667-75
pubmed: 21540404
Acta Psychiatr Scand. 2018 Aug;138(2):101-109
pubmed: 29786829
Schizophr Res. 2010 Jun;119(1-3):138-44
pubmed: 20299191
Oral Dis. 2014 Apr;20(3):e90-6
pubmed: 23731177
Nord J Psychiatry. 2018 Feb;72(2):124-129
pubmed: 29125018
J Clin Psychopharmacol. 2004 Dec;24(6):675-6
pubmed: 15538136
Clin Schizophr Relat Psychoses. 2016 Jul 25;:
pubmed: 27454214
Int Clin Psychopharmacol. 2014 Nov;29(6):313-7
pubmed: 24932886
Aust N Z J Psychiatry. 2000 Dec;34(6):1033-4
pubmed: 11127617
Biol Psychiatry. 1996 Dec 1;40(11):1132-4
pubmed: 8931916
J Psychiatry Neurosci. 1999 May;24(3):250
pubmed: 10354662
Ann Pharmacother. 1995 May;29(5):489-92
pubmed: 7655132
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005579
pubmed: 18646130
J Dent Res. 2010 Mar;89(3):276-80
pubmed: 20093673
Ann Pharmacother. 2004 Sep;38(9):1538
pubmed: 15252196
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1546-7
pubmed: 17614181
PLoS Med. 2005 May;2(5):e141
pubmed: 15916472
J Clin Psychiatry. 2009 Aug;70(8):1114-9
pubmed: 19758522
Br J Clin Pharmacol. 2001 Feb;51(2):133-42
pubmed: 11259984
Biol Psychiatry. 1996 Jun 1;39(11):946-9
pubmed: 9162206
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Psychiatr Serv. 2004 Mar;55(3):318
pubmed: 15001737
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Acta Psychiatr Scand. 2018 Jan;137(1):47-53
pubmed: 29064084
Syst Rev. 2015 Mar 06;4:23
pubmed: 25874584
Br J Psychiatry. 2016 Nov;209(5):385-392
pubmed: 27388573
Eur J Clin Pharmacol. 1983;25(3):319-22
pubmed: 6628519
Can J Psychiatry. 2007 Jun;52(6):377-84
pubmed: 17696024
Oral Dis. 2016 Jul;22(5):365-82
pubmed: 26602059
J Clin Psychopharmacol. 2017 Apr;37(2):155-161
pubmed: 28129312